Search clinical trials for: ELLIPTA inhaler

Total 1463 results

GlaxoSmithKline

Recruiting

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

Asthma

United States, Canada, Argentina, Australia, Japan, Korea, Republic of, Taiwan
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma

Asthma

Netherlands
Pulmonary Research Institute of Southeast Michigan
GlaxoSmithKline

Completed

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

COPD

United States
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

Asthma

United States, Canada, Germany, Spain, Netherlands, Italy, United Kingdom
GlaxoSmithKline

Completed

An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma

Asthma

Canada, United States
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
AstraZeneca
Parexel

Completed

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Chronic Obstructive Pulmonary Disease

Germany, United Kingdom
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
GlaxoSmithKline

Completed

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Pulmonary Disease, Chronic Obstructive

Germany, Spain, Netherlands, Sweden, United Kingdom
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
Gary L. Pierce

Completed

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

COPD

United States
GlaxoSmithKline

Completed

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Withdrawn

Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study (LEGEND)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
GlaxoSmithKline

Completed

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

Asthma

United States, Canada
GlaxoSmithKline

Completed

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Asthma

United States
GlaxoSmithKline

Withdrawn

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

Asthma
University Hospital, Bordeaux

Withdrawn

Description of the Ability to Learn How to Handle Inhaler Devices in Asthma (AUDIT)

Asthma

France
GlaxoSmithKline
RTI Health Solutions(RTI HS)

Completed

Pediatric Ease of Use ELLIPTA Items

Asthma

United States
Mundipharma Research Limited

Completed

A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma

Asthma

United Kingdom, Sweden, Australia, New Zealand, Slovakia
GlaxoSmithKline

Completed

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
Novartis Pharmaceuticals

Completed

Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

Pulmonary Disease, Chronic Obstructive (COPD)

Argentina
GlaxoSmithKline

Completed

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Estonia, Peru, Poland, France, Chile, Hungary, Italy, Slovakia
GlaxoSmithKline

Completed

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

Asthma

United States
GlaxoSmithKline

Completed

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
GlaxoSmithKline
Hammersmith Medicines Research

Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Withdrawn

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany
GlaxoSmithKline

Completed

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

Asthma

United States
GlaxoSmithKline

Completed

To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma

Asthma

United Kingdom, Netherlands
GlaxoSmithKline

Completed

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Koronis Biomedical Technologies
University of Chicago; National Institute on Aging (NIA)

Not yet recruiting

Inhaler Trainer Efficacy Study

Asthma | Copd | Acute Exacerbation of COPD
Dr. George Luciuk

Recruiting

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

Hypersensitivity | Anaphylaxis

Canada
GlaxoSmithKline

Not yet recruiting

A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

Asthma | Mild Asthma
GlaxoSmithKline

Not yet recruiting

A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive

Asthma | Healthy Participants

Netherlands
AstraZeneca
Premier HealthCare Solutions Inc.

Recruiting

Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (ANCHOR)

Asthma

United States
Institute of Liver and Biliary Sciences, India
Institute of Liver and Biliary Sciences

Recruiting

Effect of TCI Propofol on Liver Transplant (TCI) Propofol on Intra-operative Usage of Vasopressors in Liver Transplant Recipients.

Liver Transplant Recipients

India
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Universitair Ziekenhuis Brussel

Recruiting

Pharmacokinetics of Inhaled Levosimendan (Symbiov)

Left Ventricular Dysfunction

Belgium
Fundació Eurecat
Centre de Diagnosi per la Imatge; Instituto de Investigación Biomédica de Girona... and other collaborators

Not yet recruiting

Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity (FATHIS+)

Visceral Obesity | Non-alcoholic Fatty Liver | Postmenopausal

Spain
University Medical Center Groningen
Trudell Medical International

Not yet recruiting

Inhaler Adherence and Inhalation Technique Assessed by a Smart Spacer in Patients With Severe Asthma on Biologics (OUTERSPACE-3)

Asthma

Netherlands
Chung-Ang University Gwangmyeong Hospital
National Research Foundation of Korea

Recruiting

The Effect of Intravenous Versus Volatile Anesthesia on Postoperative Cognitive Dysfunction in Elderly Patients

Postoperative Cognitive Dysfunction

Korea, Republic of

3

Subscribe